Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.3.0.814
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Unaudited Consolidated Statements Of Operations        
Revenues
Operating expenses:        
Amortization & depreciation $ 44 $ 194 $ 413 $ 582
General and administrative 127,363 95,070 316,594 389,981
Total operating expenses 127,407 95,264 317,007 390,563
Loss from operations $ (127,407) (95,264) (317,007) (390,563)
Other income (expense):        
Gain (Loss) on fair value adjustment - derivatives $ 19,135 25,456 $ 10,875
Gain on debt reversal $ 108,000 108,485
Interest expense (66,964) $ (48,037) (179,482) $ (135,702)
Interest expense - beneficial conversion feature (6,250) (7,751) (17,500) (27,416)
Total other income (expense) 34,786 (36,653) (63,041) (152,243)
Loss before provision for income taxes $ (92,621) $ (131,917) $ (380,048) $ (542,806)
Provision for income tax
Net loss $ (92,621) $ (131,917) $ (380,048) $ (542,806)
Less: Net loss attributable to noncontrolling interest 1,626 1,021 3,493 3,388
Net loss attributable to TranBioTec, Inc. $ (90,995) $ (130,896) $ (376,555) $ (539,418)
Net loss per share        
(Basic and fully diluted) $ (0.00) $ (0.00) $ (0.01) $ (0.01)
Weighted average number of common shares outstanding 59,696,720 41,884,034 58,927,503 37,810,366